RNAZ
Transcode Therapeutics Inc
NASDAQ: RNAZ · HEALTHCARE · BIOTECHNOLOGY
$4.96
-0.80% today
Updated 2026-07-29
Market cap
$7.86M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-3.60
Dividend yield
—
52W range
$4 – $21
Volume
0.1M
WallStSmart proprietary scores
16
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C5.3
Quality
C+3.0
Profitability
D5.0
Valuation
C+3/9
Piotroski F-Score
Weak
-1.4
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →206 stocks currently score above 75
Price targets
Analyst target
$10.00
+101.61%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
Price chart
Stock snapshot
Strengths
Insufficient data
Risks
- Piotroski 3/9 — weak financial health
- Altman Z -1.37 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-4.98B
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-17.56M | $-18.55M | $-16.75M | $-34.66M | $-17.79M |
| EPS | — | — | — | — | $-3.60 |
| Free cash flow | $-15.86M | $-18.11M | $-13.36M | $-19.52M | $-4.98B |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
Transcode Therapeutics Inc trades at $4.96. Our Smart Value Score of 16/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of -1.37, it sits in the distress.
Frequently asked questions
What is Transcode Therapeutics Inc's stock price?
Transcode Therapeutics Inc (RNAZ) trades at $4.96.
Is Transcode Therapeutics Inc overvalued?
Transcode Therapeutics Inc carries a Smart Value Score of 16/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Transcode Therapeutics Inc (RNAZ)?
The 12-month analyst consensus target is $10.00, about 101.6% above the current $4.96. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Transcode Therapeutics Inc's Altman Z-Score is -1.37, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-27.93%
Beta1.24
50D MA$6.39
200D MA$8.81
Shares out0.00B
Float0.00B
Short ratio—
Avg volume0.1M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—